The Delhi Network of Positive People (DNP+) is calling on the EU Trade Commissioner to come clean on the demands and pressures being placed by the European Union on the Government of India to accept TRIPS-plus measures that will have a severe, adverse impact on access to safe, effective and affordable medicines in India and across the developing world.
Commerce minister Anand Sharma said on Monday that a proposed free-trade agreement (FTA) with the European Union (EU) would not hurt the generic drugs industry. The minister also said India would attract the same amount of foreign direct investment as last year.
With the looming threat of these supply lines being disrupted by TRIPS+ provisions that are likely to be demanded of the Indian Government by FTA negotiators from the European Union and Japan we request that the Indian Government stand firm on their position of refusing all TRIPS+ provision that maybe included in any final agreement.
Poor people in India and other developing countries may lose access to affordable generic drugs as part of free-trade negotiations between India and the European Union, a medical advocacy group said on Friday.
The eighth round of the FTA talks which took place in Mumbai last week have been strongly criticised in India for their secrecy and lack of consultation with the national parliament and state governments.
Whichever FTA is signed first — Japan’s or the EU’s — will put pressure on the other pair of negotiators to reach pragmatic compromises. The race for India is on.
Amid fresh talks on the India-Japan free trade agreement (FTA), concerns are being expressed about certain measures that could hamper generic drugs and access to medicines.
The European Union on Friday said it would prefer to resolve two commercial disputes with India without engaging in a legal battle at the World Trade Organisation (WTO). The first dispute involves seizure of Indian generic drugs in transit at some EU-based ports, including Amsterdam, which were bound for certain third world countries, on the grounds of patents infringement.
The bilateral free trade agreements (FTAs) India is negotiating with Japan and the European Union (EU) can lead to a sharp rise in the cost of medicines, a network of civil society groups has warned.
The European Union’s demands on India to take on higher intellectual property (IP) standards, if adopted, could spell disaster for the supply of low-cost generic medicines, undermine India’s development and set a significant precedent for the future of IPR protection globally, cautioned Dr Carlos M. Correa, an expert on IP and the WTO TRIPS Agreement.
What is slowly emerging is the beginning of a composite oppositition to FTAs in India.
The negotiating texts so far known do indicate that India is resisting many aspects of the EU demands of higher IPRs standards. Analysis by Carlos Correa.
As the sixth round of negotiations related to the EU-India Free Trade Agreement (FTA) got underway on Tuesday, the police detained a couple of representatives of public interest groups during a peaceful protest in front of the office of the European Commission (EC).
Efforts by the European Union to insert strong provisions on pharmaceutical patents in free trade agreements it is negotiating with India, Colombia, Peru and ASEAN could imperil access to medicines in developing countries, global public health activists have alleged.
India is set to ask Japan to facilitate the entry of Indian pharmaceutical companies in the world’s second-largest drug market. The matter will be raised when the two sides discuss a bilateral comprehensive economic partnership agreement.
The negotiations for the India-Japan Comprehensive Economic Partnership Agreement (CEPA) have gained momentum with the two sides moving towards a deal on allowing Indian companies that make low-cost drugs to sell in Japan.
Fearful fo the ongoing to realize a single market for the Association of Southeast Asian Nations by 2015, Filipino-owned pharmaceutical firms have asked the government to ensure that safety nets are in place for the local industry. Some are more concerned about the India-ASEAN FTA.
The Daiichi Sankyo-Ranbaxy Laboratories deal has come as a shot in the arm for India’s Comprehensive Economic Co-operation Agreement (CECA) negotiations with Japan. Indian pharma companies have been unable to break into Japan, the world’s second largest drug market, due to the country’s stringent sanitary and phytosanitary standards, technical barriers to trade (TBT) and environmental norms.
A section of India’s generic drug industry has claimed that its ability to export generic drugs to over a dozen countries with which the US is planning FTAs will increase, if a “conceptual agreement” reached last week by the US’ House of Representatives speaker Nancy Pelosi and the Bush administration is ratified and implemented.
New Indian data exclusivity patenting regulations will severely hinder generic AIDS drugs manufacturing in India, and thus less people will have access to AIDS therapy globally. The world’s poor overwhelmingly make up this population with lack of access. Because of this, moral human rights and distributive justice approaches should compel India to take an equity-oriented approach in access to AIDS medicines and reject data exclusivity regulations currently under discussion.